Omacetaxine and venetoclax in relapsed/refractory acute myeloid leukemia or myelodysplastic syndrome with mutant RUNX1.

DiNardo CD, Jen WY, Montalban-Bravo G, Wang X, Loghavi S, Lavu S, Short NJ, Chien K, Issa GC, Pemmaraju N, Yilmaz M, Andreeff M, Borthakur G, Kadia TM, Daver NG, Garcia-Manero G, Mill CP, Su X, Fiskus W, Bhalla KN.

Open source

DOI
10.1016/j.bneo.2025.100145
Published
2025-07-25
Container
Blood Neoplasia
Publisher
Not recorded
Open access
yes

Credibility signals

limited evidence Score 45/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

Cite this work

BibTeX

@article{allodium:10.1016/j.bneo.2025.100145,
  title = {Omacetaxine and venetoclax in relapsed/refractory acute myeloid leukemia or myelodysplastic syndrome with mutant RUNX1.},
  author = {DiNardo CD and  Jen WY and  Montalban-Bravo G and  Wang X and  Loghavi S and  Lavu S and  Short NJ and  Chien K and  Issa GC and  Pemmaraju N and  Yilmaz M and  Andreeff M and  Borthakur G and  Kadia TM and  Daver NG and  Garcia-Manero G and  Mill CP and  Su X and  Fiskus W and  Bhalla KN.},
  year = {2025},
  journal = {Blood Neoplasia},
  doi = {10.1016/j.bneo.2025.100145},
  url = {https://doi.org/10.1016/j.bneo.2025.100145}
}

RIS

TY  - JOUR
TI  - Omacetaxine and venetoclax in relapsed/refractory acute myeloid leukemia or myelodysplastic syndrome with mutant RUNX1.
AU  - DiNardo CD
AU  -  Jen WY
AU  -  Montalban-Bravo G
AU  -  Wang X
AU  -  Loghavi S
AU  -  Lavu S
AU  -  Short NJ
AU  -  Chien K
AU  -  Issa GC
AU  -  Pemmaraju N
AU  -  Yilmaz M
AU  -  Andreeff M
AU  -  Borthakur G
AU  -  Kadia TM
AU  -  Daver NG
AU  -  Garcia-Manero G
AU  -  Mill CP
AU  -  Su X
AU  -  Fiskus W
AU  -  Bhalla KN.
PY  - 2025
JO  - Blood Neoplasia
DO  - 10.1016/j.bneo.2025.100145
UR  - https://doi.org/10.1016/j.bneo.2025.100145
ER  - 

APA

CD, D., WY, J., G, M., X, W., S, L., S, L., NJ, S., K, C., GC, I., N, P., M, Y., M, A., G, B., TM, K., NG, D., G, G., CP, M., X, S., W, F., & KN., B. (2025). Omacetaxine and venetoclax in relapsed/refractory acute myeloid leukemia or myelodysplastic syndrome with mutant RUNX1.. Blood Neoplasia. https://doi.org/10.1016/j.bneo.2025.100145

Source records